Dentistry - Bacteriophage

Author

Bacteriophage

Joel M. Eichen

2005-02-01, 2:29 pm

Anyone want to engage in a scientific discussion about bacteriophages?

They are relatively unknown in this country due to the strong
pharmaceutical lobby. I call that Big Pharma Lobby.

But phages are used clinically in certain regions of Eastern Europe
and the Ukraine.

Joel

Matt

2005-02-03, 10:48 am

Joel M. Eichen wrote:
> Anyone want to engage in a scientific discussion about bacteriophages?
>
> They are relatively unknown in this country due to the strong
> pharmaceutical lobby. I call that Big Pharma Lobby.
>
> But phages are used clinically in certain regions of Eastern Europe
> and the Ukraine.
>
> Joel
>

I probably don't know enough to contribute much, but I would be
interested in seeing the big picture regarding their clinical use.

clintonz@prodigy.net

2005-02-03, 10:48 am

Joel M. Eichen wrote:
> Anyone want to engage in a scientific discussion about
bacteriophages?
>
> They are relatively unknown in this country due to the strong
> pharmaceutical lobby. I call that Big Pharma Lobby.
>
> But phages are used clinically in certain regions of Eastern Europe
> and the Ukraine.
>
> Joel

I wonder what their use would be in Jaw Om or similar
jaw diseases. I assume these are viruses which are able
to selectively attack certain bacteria.

Joel M. Eichen

2005-02-03, 10:48 am

On Wed, 02 Feb 2005 14:20:02 GMT, Matt <matt@themattfella.zzzz.com>
wrote:

>Joel M. Eichen wrote:
>
>I probably don't know enough to contribute much, but I would be
>interested in seeing the big picture regarding their clinical use.

**

REPLY

http://www.evergreen.edu/phage/eliava/grants.htm

Eliava Grants
Home
Phage Therapy
Addendum 2000
Alfred's Story
Companies
Polish Research
Therapy News
PhageBiotics Foundation
Projects
Ways to Give
Tbilisi Eliava Institute
Grants
Contact
Other Tbilisi People
Evergreen Research
Evergreen Phage Meetings
General Meeting Calendar
Evergreen Meeting Details
Genomics
Contact Info
Links
PostDocs
Classic Papers
Current Phage Books
International Grants involving Phage and the Eliava Institute:

-Information on the International Science and Technology Centers
(ISTC) program

-Science and Technology Centers in the Ukraine (STCU) program
-Civilian Research and Defense Fund (CRDF) program
These programs were set up to help scientists once supported by the
Soviet military make a productive transition to the civilian sector;
they are associated with the State Department and also involve Europe
and Japan. They have become very supportive of phage work - 2 State
Department representatives actually came to the last Evergreen Phage
meeting to encourage involvement in their programs.

Projects under way:

Molecular Mechanisms of Bacteriophage Evolution and Host-to-Virus
Transcription Transition During Bacteriophage Infection in Pathogenic
Bacteria. PI - Tato Gabisonia; US Dept. of Health and Human Services,
Rockville; US Partner: Konstantin Severinov, Rutgers; BTEP ISTC Grant
G587
Analysis of Phage Specific Potentially Lethal Genes and Investigation
of Antibacterial Activity of" Killer" Proteins. PIs - Mzia Kutateladze
& Rezo Adamia. US partners: Jan Drake (National Institute of
Environmental Health Sciences), Elizabeth Kutter, Charles Stewart;
BTEP ISTC Grant G595

A new strategy for control of potato bacterial diseases based on
application of specific phages. PI, Marina Tediashvili; partner: 3M;
CRDF Grant N 527

Bacteriophage - a new approach for combating of the nosocomial
respiratory infection caused by Ps. aeruginosa. PI - Nino Chanishvili,
Co-ordinator - Paul Barrow, UK, INTAS-Georgia (joint funding from EC
and Georgia) (completed)

An epidemiological study of outbreaks of B. anthraxis in Georgia. PI-
Sergo Rigvava, Co-ordinator Richard Sharp, CAMR, UK; INTAS Open Call

Regional Experimental Center for Applied and Microbiology Research
(RECAMBR). PI- Nino Chanishvili -- CRDF - Regional Experimental
Support Centers Program
Student Project 2001: Nino Chanishvili CRDF G 589

*Approved; still negotiating final research plan: [This step often
takes over a year.]
* Bacteriophages for the Treatment of Infectious Diseases Caused by
Antibiotic-Resistant Bacterial Strains of Staphylococcus Aureus and
Pseudomonas Aeruginosa. PI: Nana Balarjishvili. NATO partners: Henry
Krisch (Toulouse); Elizabeth Kutter (Evergreen) ISTC Grant G510
* Sustained/Controlled-Release Drug Devices Containing Bacteriophages
Based on New Biodegradable Poly (ester amide)s. Amiran Meipariani and
Zemphira Alavidze [Supporting institute: Georgian Technical University
/ Research Center for Medical Polymers and Biomaterials, Tbilisi,
Georgia - Ramaz Katsarava] -- ISTC Grant G589
* Monitoring and preventing the after-effects of natural hazards and
water-borne epidemics through application of phage-based techniques.
PI: Nino Chanishvili. [Supporting institutes: National Center for
Diseases Control, Tbilisi, Georgia; Geophysics Institute, Tbilisi,
Georgia. US collaborator: university of North Carolina/Carolina
Environmental Program, Partner: US Department of Health & Human
Services, Rockville, MD, BTEP ISTC Grant G608

**Waiting for granting board decisions:
** Different Medicinal Forms of Bacteriophages for Treatment and
Prevention of Bacterial Infections Induced by the Genera of
Staphylococcus and Streptococcus - Inga Georgadze; Collaborator:
University of Maryland / School of Medicine / Department of
Epidemiology and Preventive Medicine, Baltimore -- ISTC G824
** Prolonged Acting, High Effective, Antimastitis Preparation Composed
Of Bacteriophages, Hyaluronidase And Biodegradable Polymer. PI: Tato
Gabisonia; [Supporting institute: Georgian Technical university /
Research Center for Medical Polymers and Biomaterials, Tbilisi,
Georgia - Ramaz Katsarava]; US collaborator: Elizabeth Kutter -- STCU
** Study of interaction between antibiotics and bacteriophages in
vitro taking into account the resistance of strains isolated from
patients during the treatment of suppurative infections. PI: Zemphira
Alavidze. [Collaboration: Dr. Guram Gvasalia, Regional Hospital] --
STCU
** Medicinal-Prophylactic Phage Preparation Against Bacterial
Complications Induced by Proteus and Pseudomonas, in Extreme
Conditions. PIs: Liana Gachechiladze and Inga Georgadze; US
collaborator: Elizabeth Kutter - CRDF

Scientists from the Eliava Institute are also collaborators on other
international grants where the PIs are from other Georgian
institutions; CR: Eliava Institute lead collaborator
Bacteriophages Containing Drug Sustained/Controlled Release Type
Polymeric Composites - New Effective Preparations for the Treatment of
Infected Wounds and Cavities. Georgian Technical university / Research
Center for Medical Polymers and Biomaterials, Tbilisi, Georgia - Ramaz
Katsarava. Eliava Institute collaborators: Zemphira Alavidze and
Amiran Meipariani. US collaborator: Glenn Morris, university of
Maryland. ISTC Grant G446
[The Katsarava group has also been awarded a CRDF grant for
development of a Regional Research Center for work with biopolymers
and an additional ISTC grant is in the work plan-negotiation stages;
these are clearly both also relevant to the goal of commercially
making Phage Bioderm, which incorporates phages obtained from the
Eliava Institute.]

The Biological Dispersion Phenomenon and the Energetic of
Microplankton: A Search for the Regularities and the Relationship to
Environmental Fluctuations. CR Marina Tediashvili, Co-ordinator
Professor Richard Kemp university of Wales, UK, INTAS Grant N 1390

Prevention of food spoilage by suppression of phenoloxidase
perioxidase and growth of pathogenic micro-flora by use of natural
inhibitors of plant origin. CR Marina Tediashvili, Co-ordinator , Jose
Neptuno Rodrigues Lopes, university of Mursia, Spain- INTAS FOOD-2000

Evaluation of coastal pollution status and bio-indicators for the
Black Sea (BIOBS). CR, Marina Tediashvili, Co-ordinator James Wilson,
Center for the Environment Trinity College, Dublin, Ireland
INTAS-Polluted Environments

Bacteriophage against a number of medication resistant conditionally -
pathogenic bacteria as an alternative to antibiotics. Biochimpharm
Joint Stock Company (Golidjashvili Aleksandr Otarovich); Eliava
Co-PI:Liana Gachechiladze. NATO collaborators: Humboldt University
School of Medicine Charite, the Institute of Virology, Berlin;
Elizabeth Kutter, Evergreen State college *ISTC Grant G534

Tuberculosis Bacteriophage: Development of Obtainment and Application
Methods. Sergey Vashakidze Institute of Tuberculosis and Pulmonology,
Tbilisi, Georgia; US collaborators: Merlin Technologies, Inc., Boston,
MA; Public Health Research Institute, New York ** ISTC Grant G591

return to top

For more information contact Dr. Elizabeth Kutter at
phagebiotics@attbi.com.

web counter tracks new visitors

Last Updated: February 02, 2005
Site Manager: Gautam Dutta

The Evergreen State College
2700 Evergreen Parkway NW
Olympia, WA 98505
(360) 867-6000

Joel M. Eichen

2005-02-03, 10:48 am

On 2 Feb 2005 10:55:23 -0800, clintonz@prodigy.net wrote:

>I wonder what their use would be in Jaw Om or similar
>jaw diseases. I assume these are viruses which are able
>to selectively attack certain bacteria.

YES!

What are jaw Om diseases?

Joel

clintonz@prodigy.net

2005-02-03, 10:48 am

Joel M. Eichen wrote:
> On 2 Feb 2005 10:55:23 -0800, clintonz@prodigy.net wrote:
>
>
>
> YES!
>
> What are jaw Om diseases?
>
>
> Joel

Jaw Osteomyeltis. However someone pointed out that frequntly
bacterial infections create biofilms which seem to protect them from
these phages

Joel M. Eichen

2005-02-03, 10:48 am

On 2 Feb 2005 16:14:36 -0800, clintonz@prodigy.net wrote:

>
>Jaw Osteomyeltis. However someone pointed out that frequntly
>bacterial infections create biofilms which seem to protect them from
>these phages

Very unusual, I hope you are not referring to NICO.

Joel

Here is some NIH material

Definition Return to top

Osteomyelitis is an acute or chronic bone infection, usually caused by
bacteria.
Causes, incidence, and risk factors Return to top

The infection that causes osteomyelitis often is in another part of
the body and spreads to the bone via the blood. Affected bone may have
been predisposed to infection because of recent trauma.

In children, the long bones are usually affected. In adults, the
vertebrae and the pelvis are most commonly affected. Bone infection
can be caused by bacteria or by fungus. When the bone is infected, pus
is produced within the bone, which may result in an abscess. The
abscess then deprives the bone of its blood supply.

Chronic osteomyelitis results when bone tissue dies as a result of the
lost blood supply. Chronic infection can persist intermittently for
years.

Risk factors are recent trauma, diabetes, hemodialysis, and
intravenous drug abuse. People who have had their spleen removed are
also at higher risk for osteomyelitis.

The incidence of osteomyelitis is 2 in 10,000 people.

Symptoms Return to top

Pain in the bone
Local swelling, redness, and warmth
Fever
Nausea
General discomfort, uneasiness, or ill feeling (malaise)
Drainage of pus through the skin (in chronic osteomyelitis)
Additional symptoms that may be associated with this disease:
Excessive sweating
Chills
Low back pain
Swelling of the ankles, feet, and legs
Signs and tests Return to top

A physical examination shows bone tenderness and possibly swelling and
redness.

A bone scan indicates infected bone.
A CBC shows elevated white blood cell count.
The ESR is elevated.
Blood cultures may help identify the causative organism.
An MRI and a needle aspiration of the area around infected bones for
culture may be done.
A bone lesion biopsy and culture may be positive for the organism.
A skin lesion with a sinus tract (the lesion "tunnels" under the
tissues) may yield drainage of pus for culture.
This disease may alter the results of the following tests:
Joint x-ray
Hand x-ray
Extremity x-ray
Bone x-ray
ALP (alkaline phosphatase) isoenzyme
ALP
Treatment Return to top

The objective of treatment is to eliminate the infection and prevent
the development of chronic infection.

Intravenous antibiotics are started early and may later be changed
depending on culture results. Some new antibiotics can be very
effective when given orally.

In chronic infection, surgical removal of dead bone tissue is usually
necessary. The open space left by the removed bone tissue may be
filled with bone graft or by packing material to promote the growth of
new bone tissue. Antibiotic therapy is continued for at least 3 weeks
after surgery.

clintonz@prodigy.net

2005-02-03, 10:48 am

As i said before I have chronic Om diagnosed by biopsy. The "trauma"
probably
being excessive Hg leakage from a filling near that location (or the
fashionable
term these days being Hg reabsorption). It kills the bone blood supply
allowing bacteria to get in. I don't have any nerve pain and I don't
want to get into a debate about whether OM/ON causes nerve pain,
although you might want to
look at this:

Jawbone cavities and trigeminal and atypical facial neuralgias.

Ratner EJ, Person P, Kleinman DJ, Shklar G, Socransky SS.

Oral Surg Oral Med Oral Pathol 1979 Jul;48(1):3-20

http://www.ncbi.nlm.nih.gov/entrez/...4&dopt=Abstract

The possible role of dental and oral disease in the etiology of
idiopathic trigeminal and atypical facial neuralgias has been examined.
Among thirty-eight patients with idiopathic trigeminal neuralgia and
twenty-three patients with atypical facial neuralgia, there was in
nearly all instances a close relationship between pain experienced and
the existence of cavities in alveolar bone and jawbone of the patients.
The cavities were at the sites of previous tooth extractions and,
although at times more than 1 cm. in a given diameter, were usually not
detectable by x-rays. A new method for their detection and localization
was developed empirically, based on the observation that peripheral
infiltration of local anesthetic into or very close to the bone cavity
rapidly abolished trigger and pain perception by patients during
persistence of the anesthetic action. Histopathologic examination of
bone removed from cavities by curettage revealed, in both idiopathic
trigeminal and atypical facial neuralgias, a similar pattern
characterized by a highly vascular abnormal healing response of bone.
Some lesions presented a mild chronic inflammatory (lymphocytic)
infiltration. Preliminary microbiologic studies of material from the
walls of the cavities showed the existence within them of a complex,
mixed polymicrobial aerobic and anaerobic flora. Treatment consisted of
vigorous curettage of the bone cavities, repeated if necessary, plus
administration of antibiotics to induce healing and filling-in of the
cavities by new bone. Responses of patients to the above treatment
consisted of marked to complete pain remissions, the longest of which
has been for 9 years. Complete healing leads to complete and persistent
pain remissions. It was concluded that in both idiopathic trigeminal
and atypical facial neuralgias, dental and oral pathoses may be major
etiologic factors.

I'd be very interested to hear your scientific respone to this
article

W_B

2005-02-03, 10:48 am

On Wed, 02 Feb 2005 18:00:00 -0500, Joel M. Eichen
<joeleichen@yahoo.com> wrote:

>On 2 Feb 2005 10:55:23 -0800, clintonz@prodigy.net wrote:
>
>
>
>YES!
>
>What are jaw Om diseases?
>
>
>Joel
>
Tired jaws after repeating a mantra ?

--
W_B

wubbabubbazG@RBAGEyahoo.com
Take out the G'RBAGE

Joel M. Eichen

2005-02-03, 10:48 am

On 2 Feb 2005 18:00:54 -0800, clintonz@prodigy.net wrote:

>As i said before I have chronic Om diagnosed by biopsy. The "trauma"
>probably
>being excessive Hg leakage from a filling near that location (or the
>fashionable

True, those 17 micrograms can cause some big damage.

Where is this substantiated in the dental literature?

Joel

Joel M. Eichen

2005-02-03, 10:48 am

On Thu, 03 Feb 2005 04:01:05 GMT, W_B <no_one@nowhere.net> wrote:

>On Wed, 02 Feb 2005 18:00:00 -0500, Joel M. Eichen
><joeleichen@yahoo.com> wrote:
>
>Tired jaws after repeating a mantra ?

Jaw Om Shanti diseases?

clintonz@prodigy.net

2005-02-07, 8:26 am

Joel M. Eichen wrote:
> On 2 Feb 2005 18:00:54 -0800, clintonz@prodigy.net wrote:
>
>
>
> True, those 17 micrograms can cause some big damage.
>
> Where is this substantiated in the dental literature?
>
> Joel

The idiociy of this argument is that no one on this
list can state an upper limit on elemental (or methyl)
Hg release from amalgam in practice. Your underlying premise is that
all amalgam gives off a well distributed amount of
Hg which is exactly 17 ug for each fillings, which is false.

As for heavy metal exposure causing jaw bone problems
that is well known, only you and other dentists
seem to think that if Hg comes from amalgam it is safe.
Why would I care what the dental literature says (not that
I have searched for it), when the dental literature denied amalgam had
a vapor pressure until 10 years ago. Even a monkey could comprehend
that if excessive Hg can cause bone damage in an
industrial setting , then unusal Hg leakage from amalgam could cause
the same thing.

Did you see the article I posted? You seem to know as much
about OM as you do about amalgam and Hg

Joel M. Eichen

2005-02-07, 8:26 am

On 3 Feb 2005 08:52:40 -0800, clintonz@prodigy.net wrote:

>The idiociy of this argument is that no one on this
>list can state an upper limit on elemental (or methyl)
>Hg release from amalgam in practice. Your underlying premise is that
>all amalgam gives off a well distributed amount of
>Hg which is exactly 17 ug for each fillings, which is false.

Jan told me it was exactly seventeen micrograms ......

Joel M. Eichen

2005-02-07, 8:26 am

On 3 Feb 2005 08:52:40 -0800, clintonz@prodigy.net wrote:

> Even a monkey could comprehend
>that if excessive Hg can cause bone damage in an
>industrial setting , then unusal Hg lea

Send bananas, FedEx.

W_B

2005-02-12, 1:30 pm

Joel M. Eichen

2005-02-12, 1:30 pm

Joel M. Eichen

2005-02-12, 1:30 pm